The human body possesses an extraordinary capacity for repair. Regenerative cellular therapy leverages the body’s own signaling mechanisms — using ethically sourced human cellular and tissue-based products (HCT/Ps) — to support the biological environment where healing occurs. At Longitude Life, we offer physician-supervised regenerative protocols using premium allogenic biologics from FDA-registered, AATB-accredited, and CLIA-certified laboratories.

This is not a menu of injections. It’s a clinically directed program built on the most rigorously sourced, tested, and documented regenerative biologics available in the United States.

Our Laboratory Partners

We partner with two U.S.-based, world-renowned laboratories with the highest credentials in the regenerative biologics industry.

Our Partners are AATB-accredited, cGMP-certified, FDA-registered tissue banks and life sciences companies with multiple FDA-approved Investigational New Drug (IND) applications — including the first-ever IND combining umbilical cord mesenchymal stem cells (UC-MSCs) and MSC-derived exosomes for IV therapeutic use. This lab bio-ethically sources human birth tissue from umbilical cord and placenta, and is actively conducting Phase II clinical trials across multiple disease models including pulmonary fibrosis and premature ovarian insufficiency. Their proprietary process includes triple-layer donor screening, three-generation family medical history review, and comprehensive pathogen testing with a 14-day lot quarantine before any product is released. All biologics are sourced exclusively from healthy, full-term C-section deliveries through direct OBGYN partnerships — ensuring 100% chain of custody from delivery room to clinic. Products are processed for homologous use as HCT/Ps under FDA regulations.

Together, these partnerships give Longitude Life access to the most rigorously sourced, tested, and documented regenerative biologics available in the United States.

Treatment Modalities

Longitude Life offers multiple delivery routes, each selected by the treating physician based on the patient’s condition, goals, and medical history. The route of administration determines how the biologic interacts with the target tissue environment.

Joint Injections

Patients experiencing joint discomfort associated with cartilage wear, soft tissue injury, or age-related degeneration. Common sites include knee, shoulder, hip, elbow, wrist, and ankle.

Joint injections utilize allogenic placental-derived extracellular matrix (EXM) products containing collagens, growth factors, and native mesenchymal stem cell populations. When introduced into the joint space, these biologics provide a structural scaffold and signaling environment that may support the body’s natural repair processes. Exosome preparations may be used in conjunction to deliver concentrated cellular communication molecules — cytokines, miRNA, and growth factors — that may further support the local tissue environment.

Spinal Applications

Intradiscal Injections — For patients with disc-related concerns, biologics may be delivered directly into the disc space under image guidance. The extracellular matrix scaffold may support the structural integrity of the disc environment.

Epidural Delivery — Biologic preparations may be administered into the epidural space to support the tissue environment surrounding spinal structures.

Facet Joint Injections — Targeted delivery to facet joints may provide localized support for spinal segment comfort and mobility.

All spinal procedures are performed under fluoroscopic or ultrasound guidance by a qualified physician.

IV Exosome Infusions

Intravenous administration of exosome preparations allows for systemic distribution throughout the body. Exosomes are nano-sized extracellular vesicles (30–150 nm) that carry bioactive cargo including proteins, lipids, mRNA, and miRNA. Research suggests these vesicles participate in intercellular communication and may support systemic immune modulation and tissue maintenance. IV protocols are administered under direct medical supervision with appropriate monitoring.

Intranasal Exosome Administration

The intranasal route offers a unique pathway that may bypass the blood-brain barrier, allowing exosome preparations to reach the central nervous system more directly. Preclinical research suggests that MSC-derived exosomes administered intranasally may support neurological tissue environments. This modality is offered as an investigational option for patients interested in neurological wellness support, following thorough medical evaluation.

Hair Restoration with MSCs & Exosomes

Hair thinning and loss are driven by follicular miniaturization, reduced blood supply to the dermal papilla, and chronic scalp inflammation. Regenerative scalp injections introduce MSC-derived exosomes and extracellular matrix components directly into the scalp at the level of the hair follicle. Preclinical and early clinical research suggests that exosomal cargo — including growth factors such as VEGF, PDGF-AA, and IGF — may support angiogenesis around the follicular unit, modulate the local inflammatory environment, and promote signaling pathways associated with the hair growth cycle.

Scalp protocols typically involve a series of micro-injection sessions spaced over several weeks, often combined with microneedling to enhance delivery and stimulate the scalp’s own repair response. Patients may begin to notice changes in hair density and texture over the course of several months as the follicular environment responds. This approach may be appropriate for individuals experiencing early to moderate thinning who are seeking a non-surgical, biologic-based option.

Facial Rejuvenation & Skin Quality

The facial skin undergoes cumulative collagen loss, reduced extracellular matrix integrity, and diminished cellular turnover with age and UV exposure. Exosome-based facial protocols deliver concentrated bioactive vesicles — rich in anti-inflammatory cytokines, tissue-remodeling proteins, and regenerative miRNAs — into the dermal and subdermal layers.

Published research on adipose-derived and umbilical cord MSC exosomes applied in combination with microneedling or fractional laser has demonstrated improvements in skin texture, hydration, and fine line appearance in prospective clinical studies. The exosomal cargo may support fibroblast activity, collagen synthesis, and the skin’s natural turnover cycle without the use of synthetic fillers or neurotoxins.

Facial applications at Longitude Life include:

Exosome Facial Infusion — Topical and micro-injection delivery of exosome concentrate following microneedling, supporting the skin’s repair environment at a cellular level
Post-Procedure Recovery Support — Exosome application following laser resurfacing, chemical peels, or other aesthetic procedures to support the healing timeline and tissue quality
Under-Eye & Décolletage Rejuvenation — Targeted delivery to areas of thin, delicate skin where collagen support and microcirculation are particularly important
Scar & Texture Refinement — Exosome and ECM preparations may support remodeling in areas of scarring or uneven texture by providing the signaling environment associated with organized tissue repair

Additional Applications

Soft tissue support (tendons, ligaments)
Wound healing support
Sexual wellness protocols

U.S. Placental MSCs vs. Offshore Expanded Cells

Understanding the difference between the biologics available in the United States and those marketed at offshore clinics — particularly in Mexico, Colombia, and parts of the Caribbean — is critical for patient safety.

Cell Source — Longitude Life uses ethically sourced perinatal tissue (placenta, umbilical cord) from healthy, full-term C-section deliveries. Offshore clinics often use culture-expanded cells of uncertain provenance, sometimes from adipose or bone marrow with heavy manipulation.

Manipulation — Our biologics are minimally manipulated per FDA 21 CFR 1271, maintaining original regenerative capacity. Extensively expanded cells lose potency with each passage generation.

Regulatory Oversight — All our products come from FDA-registered, AATB-accredited, CLIA-certified labs with cGMP processing and 361 HCT/P compliance. Offshore facilities may lack equivalent oversight, standardized testing, or enforceable quality standards.

Donor Screening — Our labs conduct triple-layer screening with three-generation family medical history and a 14-day quarantine with pathogen testing. Offshore screening protocols vary widely and may lack comprehensive multi-generational health review.

Chain of Custody — 100% documented from delivery room to clinic through direct OBGYN partnerships. Offshore tissue may pass through multiple intermediaries with extended and unclear storage timelines.

Potency — Master cells from original material with full regenerative signaling capacity. Culture-expanded cells lose signaling potency at each passage, resulting in diminishing biological activity.

Cost — Competitive U.S. pricing with no travel risk or international medical complications. Offshore programs often run $15,000–$50,000+ including travel, lodging, and follow-up complications.

Quality, Safety & the Evidence Base

Allogenic (donor-derived) biologics sourced from perinatal tissues — including placental membrane, umbilical cord, and Wharton’s Jelly — are recognized for their rich concentration of bioactive factors. Peer-reviewed literature documents that placental-derived biomaterials possess biocompatible, anti-inflammatory, antimicrobial, antifibrotic, and immunomodulatory properties. Over 31 registered clinical trials are exploring MSC-derived exosomes across multiple disease models, and our laboratory partners hold multiple FDA-approved INDs for combination MSC and exosome therapies — a first-of-its-kind designation.

Perinatal tissue carries unique immunogenic suppressant properties, meaning it is universally well-tolerated and does not require donor-recipient matching — a significant advantage over autologous (self-derived) approaches that require invasive harvest procedures.

Our safety protocols include:

Comprehensive medical evaluation and health history review prior to any treatment
Physician-directed patient selection — not everyone qualifies for regenerative protocols
All biologics sourced exclusively from FDA-registered, AATB-accredited, CLIA-certified facilities
Image-guided procedures (fluoroscopy/ultrasound) for all spinal and select joint applications
Informed consent with full disclosure of investigational status and realistic expectations
Post-treatment monitoring and follow-up protocols

Is Regenerative Therapy Right for You?

Not every patient is a candidate for regenerative cellular therapy. Our physician-led evaluation process considers your complete health picture before recommending any protocol.

You may be a candidate if you:

Experience persistent joint discomfort that has not responded adequately to conventional approaches
Are exploring alternatives before or after surgical intervention
Seek support for spinal disc or soft tissue concerns
Are interested in whole-body wellness and systemic support through IV exosome protocols
Are interested in neurological wellness through investigational intranasal protocols
Are seeking non-surgical, biologic-based options for hair restoration or skin rejuvenation

You may not qualify if you have:

Active infections, certain autoimmune conditions, or active malignancies
Uncontrolled systemic conditions that may compromise safety
Medical history that the physician determines presents elevated risk

A thorough evaluation ensures we only proceed when the potential benefit-to-risk profile is favorable for you as an individual.

These products and therapies are investigational. They have not been approved by the FDA for the treatment, cure, or prevention of any disease or medical condition. Individual results may vary. Not all patients qualify for treatment. A comprehensive medical evaluation is required before any regenerative protocol is initiated. Regenerative cellular therapy products discussed herein are human cellular and tissue-based products (HCT/Ps) regulated under FDA 21 CFR Part 1271, processed for homologous use and minimally manipulated per applicable FDA guidance. References to clinical trials, research, or published literature are provided for informational context and do not constitute claims of efficacy for any specific product or protocol offered at this clinic.

Stem Cells & Exosomes